The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection

Jagdish N Sharma 1

Affiliations

01 January 2005

-

doi: 10.1163/156856005774382760

Abstract

Kinin is an important mediator of hyperalgesia, inflammatory conditions and asthma. It causes pain, inflammation, increased vascular permeability and vasodilatation. Several kinin antagonists have been developed with the aim of treating these pathologies. Kinin B2 receptor agonists and kallikrein may have clinical utility in the treatment of hypertension, left ventricular hypertrophy, ischemic heart disease, congestive heart failure and diabetes. However, there is a need to know whether there is a safe therapeutic window between potential cardio-protective and pro-inflammatory effects following administration of kinin B2 receptor agonists.

Similar articles

Cardiovascular properties of the kallikrein-kinin system.

Sharma JN, Sharma J.Curr Med Res Opin. 2002;18(1):10-7. doi: 10.1185/03007990212500093.PMID: 11999140 Review.

Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists.

Sharma JN, Al-Sherif GJ.ScientificWorldJournal. 2006 Oct 9;6:1247-61. doi: 10.1100/tsw.2006.226.PMID: 17041716 Free PMC article. Review.

Therapeutic prospects for bradykinin receptor agonists in the treatment of cardiovascular diseases.

Sharma JN, Thani RB.IDrugs. 2004 Oct;7(10):926-34.PMID: 15478018 Review.

The kallikrein-kinin system: current and future pharmacological targets.

Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A.J Pharmacol Sci. 2005 Sep;99(1):6-38. doi: 10.1254/jphs.srj05001x.PMID: 16177542 Review.

The kallikrein/kinin system and kinin antagonists in trauma.

Rodell TC.Immunopharmacology. 1996 Jun;33(1-3):279-83. doi: 10.1016/0162-3109(96)00071-9.PMID: 8856162 Review.

Cited by

The Antifibrotic and the Anticarcinogenic Activity of Capsaicin in Hot Chili Pepper in Relation to Oral Submucous Fibrosis.

Huang Z, Sharma M, Dave A, Yang Y, Chen ZS, Radhakrishnan R.Front Pharmacol. 2022 May 4;13:888280. doi: 10.3389/fphar.2022.888280. eCollection 2022.PMID: 35600864 Free PMC article. Review.

Increased Reactive Oxygen Species Generation Contributes to the Atherogenic Activity of the B2 Bradykinin Receptor.

Perhal A, Wolf S, Jamous YF, Langer A, Abd Alla J, Quitterer U.Front Med (Lausanne). 2019 Feb 21;6:32. doi: 10.3389/fmed.2019.00032. eCollection 2019.PMID: 30847343 Free PMC article.

Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation.

Wang G, Zhang Q, Yuan W, Wu J, Li C.Int J Mol Med. 2016 Nov;38(5):1463-1473. doi: 10.3892/ijmm.2016.2737. Epub 2016 Sep 15.PMID: 27633002 Free PMC article.

The role of the kallikrein-kinin system genes in the salt sensitivity of blood pressure: the GenSalt Study.

Gu D, Zhao Q, Kelly TN, Hixson JE, Rao DC, Cao J, Chen J, Li J, Chen J, Ji X, Hu D, Wang X, Liu DP, He J.Am J Epidemiol. 2012 Oct 1;176 Suppl 7(Suppl 7):S72-80. doi: 10.1093/aje/kws277.PMID: 23035147 Free PMC article. Clinical Trial.

The kinin system in hypertensive pathophysiology.

Sharma JN.Inflammopharmacology. 2013 Feb;21(1):1-9. doi: 10.1007/s10787-012-0137-5. Epub 2012 Apr 17.PMID: 22527353 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Exp Toxicol Pathol. 1994 Dec;46(6):421-33 - PubMed
  2.  
    1. Eur J Rheumatol Inflamm. 1991;11(2):30-7 - PubMed
  3.  
    1. Circ Res. 1972 Mar;30(3):358-62 - PubMed
  4.  
    1. J Clin Pharmacol. 2003 Nov;43(11):1187-95 - PubMed
  5.  
    1. Gen Pharmacol. 1996 Jan;27(1):133-6 - PubMed
  6.  
    1. Int Immunopharmacol. 2003 Mar;3(3):329-34 - PubMed
  7.  
    1. Br J Pharmacol Chemother. 1966 Jan;26(1):17-26 - PubMed
  8.  
    1. J Hypertens Suppl. 1993 Dec;11(5):S96-7 - PubMed
  9.  
    1. J Pathol. 1971 May;104(1):15-29 - PubMed
  10.  
    1. Curr Med Res Opin. 2002;18(1):10-7 - PubMed
  11.  
    1. Cardiovasc Res. 1995 May;29(5):658-63 - PubMed
  12.  
    1. Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):189-93 - PubMed
  13.  
    1. J Pharmacol Exp Ther. 1992 Jan;260(1):384-92 - PubMed
  14.  
    1. Circulation. 1996 Jul 1;94(1):44-51 - PubMed
  15.  
    1. Pharmacology. 1995 Jun;50(6):363-9 - PubMed
  16.  
    1. Int J Cardiol. 1998 Feb 28;63(3):229-35 - PubMed
  17.  
    1. Br J Pharmacol. 1990 Oct;101(2):382-6 - PubMed
  18.  
    1. Inflammopharmacology. 1998;6(1):9-17 - PubMed
  19.  
    1. Pharmacology. 2004 Apr;70(4):201-5 - PubMed

Page Navigation